Product category:
Clinical chemistry analysis
News Release from: Siemens Healthcare Diagnostics | Subject: Future Diagnostics assays
Edited by the Laboratorytalk Editorial
Team on 23 November 2005
Immunodiagnostics assays under
development
Two of the assays will add to Bayer's fertility panel, while the others will monitors foetal maturity and well-being, and the diagnosis of deep vein thrombosis or pulmonary embolism
Bayer Healthcare Diagnostics Division and Future Diagnostics, an immunoassay research and development diagnostics company, have announced a contract agreement for Future Diagnostics to develop a suite of immunoassays for Bayer In the first phase of the agreement, four immunoassays will be developed
This article was originally published on Laboratorytalk on 28 Feb 2003 at 8.00am (UK)
Related stories
Automated method for cerebrospinal fluid analysis
The first CSF assay to be released for use on a routine haematology analyser has received clearance from the US Food and Drug Administration
High-throughput HBV testing
A complete panel of automated bepatitis B assays for microbiology laboratories provides a 'total solution' for high-throughput viral serology
Two of the assays, Sex Hormone-Binding Globulin (SHBG) and Dehydroepiandrosterone Sulphate (DHEA-s) will add to Bayer Diagnostics's comprehensive fertility panel.
The other assays to be developed are Unconjugated (Free) estriol (uE3), which monitors foetal maturity and well-being, and D-dimer, for the diagnosis of deep vein thrombosis or pulmonary embolism.
According to Tom Warekois, senior vice president of global strategic marketing for Bayer HealthCare's Diagnostics Division, "Bayer Diagnostics's agreement with Future Diagnostics allows us to fulfil our commitment of expanding our immunoassay menu on our Advia Centaur family of instruments including the Advia Centaur immunoassay system, and the Advia Centaur CP immunoassay system.
"In response to market drivers and customer requests, there is a need for labs to consolidate their laboratory instruments.
"Working in parallel with Future Diagnostics, we will expedite new assays to the market to meet the lab's needs".
The companies are in discussions to expand the agreement with additional assays.
Bayer's relationship with Future Diagnostics began in 2001, when it developed an intact PTH assay for Bayer's Advia Centaur immunoassay system.
• Siemens Healthcare Diagnostics: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
